AU5533200A - Pharmaceutical composition containing sibutramine and orlistat - Google Patents

Pharmaceutical composition containing sibutramine and orlistat Download PDF

Info

Publication number
AU5533200A
AU5533200A AU55332/00A AU5533200A AU5533200A AU 5533200 A AU5533200 A AU 5533200A AU 55332/00 A AU55332/00 A AU 55332/00A AU 5533200 A AU5533200 A AU 5533200A AU 5533200 A AU5533200 A AU 5533200A
Authority
AU
Australia
Prior art keywords
compound
formula
treatment
obesity
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU55332/00A
Other languages
English (en)
Inventor
David John Heal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott GmbH and Co KG
Original Assignee
Abbott GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott GmbH and Co KG filed Critical Abbott GmbH and Co KG
Publication of AU5533200A publication Critical patent/AU5533200A/en
Assigned to ABBOTT GMBH & CO. KG reassignment ABBOTT GMBH & CO. KG Alteration of Name(s) of Applicant(s) under S113 Assignors: KNOLL AKTIENGESELLSCHAFT
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU55332/00A 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat Abandoned AU5533200A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9914744.9A GB9914744D0 (en) 1999-06-24 1999-06-24 Therapeutic agents
GB9914744 1999-06-24
PCT/EP2000/005542 WO2001000205A1 (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Publications (1)

Publication Number Publication Date
AU5533200A true AU5533200A (en) 2001-01-31

Family

ID=10855955

Family Applications (1)

Application Number Title Priority Date Filing Date
AU55332/00A Abandoned AU5533200A (en) 1999-06-24 2000-06-16 Pharmaceutical composition containing sibutramine and orlistat

Country Status (21)

Country Link
EP (1) EP1187606A1 (bg)
JP (1) JP2003503349A (bg)
KR (1) KR20020015357A (bg)
CN (1) CN1358092A (bg)
AU (1) AU5533200A (bg)
BG (1) BG106180A (bg)
BR (1) BR0011880A (bg)
CA (1) CA2375972A1 (bg)
CZ (1) CZ20014613A3 (bg)
GB (1) GB9914744D0 (bg)
HK (1) HK1049278A1 (bg)
HU (1) HUP0201878A3 (bg)
IL (1) IL147079A0 (bg)
MX (1) MXPA01012936A (bg)
NO (1) NO20016224L (bg)
PL (1) PL352402A1 (bg)
RU (1) RU2229289C2 (bg)
SK (1) SK18242001A3 (bg)
TR (1) TR200103699T2 (bg)
WO (1) WO2001000205A1 (bg)
ZA (1) ZA200109989B (bg)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696495B2 (en) * 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US20040214804A1 (en) * 2003-04-25 2004-10-28 Pharmacia Corporation Combination of an aldosterone receptor antagonist and an anti-obesity agent
BRPI0517434A (pt) 2004-10-25 2008-10-07 Solvay Pharm Gmbh composições farmacêuticas compreendendo antagonistas do receptor canabinóide cb1 e abridores de canal de potássio para o tratamento de diabetes mellitus do tipo i, obesidade e estados relacionados
US8604244B2 (en) 2010-07-02 2013-12-10 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
CA2663254C (en) 2006-09-15 2016-04-19 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR20080046601A (ko) * 2006-11-22 2008-05-27 에스케이케미칼주식회사 보관안정성이 우수한 시부트라민 함유 포접복합체
CN101890017A (zh) * 2009-05-22 2010-11-24 北京奥萨医药研究中心有限公司 含有西布曲明和他汀类降脂药物的药物组合物及其用途
MX336980B (es) * 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
RU2642074C2 (ru) 2011-12-30 2018-01-24 Ревива Фармасьютикалс, Инк. Композиции, синтез и способы применения производных фенилциклоалкилметиламина

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9727131D0 (en) * 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents

Also Published As

Publication number Publication date
GB9914744D0 (en) 1999-08-25
SK18242001A3 (sk) 2003-02-04
BG106180A (bg) 2002-08-30
TR200103699T2 (tr) 2002-04-22
HK1049278A1 (zh) 2003-05-09
CA2375972A1 (en) 2001-01-04
MXPA01012936A (es) 2004-04-21
EP1187606A1 (en) 2002-03-20
HUP0201878A2 (hu) 2003-08-28
IL147079A0 (en) 2002-08-14
WO2001000205A1 (en) 2001-01-04
HUP0201878A3 (en) 2005-04-28
NO20016224D0 (no) 2001-12-19
CZ20014613A3 (cs) 2003-04-16
CN1358092A (zh) 2002-07-10
RU2229289C2 (ru) 2004-05-27
KR20020015357A (ko) 2002-02-27
PL352402A1 (en) 2003-08-25
BR0011880A (pt) 2002-03-19
ZA200109989B (en) 2003-02-26
JP2003503349A (ja) 2003-01-28
NO20016224L (no) 2002-02-12

Similar Documents

Publication Publication Date Title
US6403641B2 (en) Therapeutic agents
US6376554B1 (en) Method of treating sexual dysfunction
US6376552B1 (en) Treatment of gallstones
AU5533200A (en) Pharmaceutical composition containing sibutramine and orlistat
US6441046B1 (en) Control of metabolism
AU5815100A (en) Therapeutic agents
US6346549B1 (en) Treatment of pharmacology of drug misuse and other addictive disorders
AU773490B2 (en) Treatment of osteoarthritis
US6403650B1 (en) Treatment of pulmonary hypertension
US6433020B1 (en) Treatment of cardiovascular disease
MXPA00006201A (en) Pharmaceutical composition containing sibutramine and orlistat
CA2367045A1 (en) Treatment of certain cancers associated with weight gain
WO2000056316A1 (en) Treatment of gallstones
EP1162966A1 (en) Weight loss after pregnancy

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: ABBOTT GMBH AND CO. KG

Free format text: THE FORMER OWNER WAS: KNOLL AKTIENGESELLSCHAFT